Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyHead and Neck OncologyThoracic TumorsTumor, regardless of entityDiseaseLung Carcinoma, Non-Small CellThyroid CancerTumor Biomarker DefinedSubgroupHER2+RET fusion positiveICD10C34.-C73MeSHNeoplasmsThyroid NeoplasmsSequenceChemotherapyChemo-substanceSelpercatinibTrastuzumab emtansineChemo-substanceSelpercatinibTrastuzumab emtansineChemo-substanceSelpercatinibTrastuzumab emtansineChemo-substanceSelpercatinibTrastuzumab emtansineNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronNo. Substances2Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAstheniaConstipationDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)HeadacheHepatotoxicityHypertensionNeuropathyNeutropeniaPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorDrilon AJhaveri KLDiseaseRET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1OriginMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Protocols in Revision 2 protocols foundProtocols under revision.Selpercatinib 160, Tumor Biomarker Defined (PID1732 V1.0)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677 V1.0)
